ADHD Medication Trends in Turkey: 2009-2013

J Atten Disord. 2017 Dec;21(14):1192-1197. doi: 10.1177/1087054714523129. Epub 2014 Jan 1.

Abstract

Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013.

Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the November 2008 to October 2013 period. Defined daily dose (DDD) of each drug was calculated according to WHO definitions and time-series analysis was conducted.

Results: There was a significant seasonal effect for prescription of all drugs. Annual use of ADHD medications increased 2.18 times for all ADHD medications combined. DDDs per 1,000 population per day for all ADHD medications were 0.28 in 2009, 0.41 in 2010, 0.52 in 2011, and 0.59 in 2012. OROS MPH represented almost 75% of all ADHD medication utilization.

Conclusion: As reported from several other countries, ADHD medication use increased in Turkey. Results suggested that over- and underdiagnosis might be seen at the same time.

Keywords: ADHD; atomoxetine; medication trends.; methylphenidate.

MeSH terms

  • Adrenergic Uptake Inhibitors / administration & dosage*
  • Atomoxetine Hydrochloride / administration & dosage*
  • Atomoxetine Hydrochloride / therapeutic use
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / epidemiology
  • Central Nervous System Stimulants / administration & dosage*
  • Central Nervous System Stimulants / therapeutic use
  • Child
  • Databases, Factual
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Prescriptions
  • Female
  • Humans
  • Male
  • Methylphenidate / administration & dosage*
  • Methylphenidate / therapeutic use
  • Practice Patterns, Physicians' / statistics & numerical data
  • Practice Patterns, Physicians' / trends*
  • Seasons
  • Treatment Outcome
  • Turkey / epidemiology

Substances

  • Adrenergic Uptake Inhibitors
  • Central Nervous System Stimulants
  • Delayed-Action Preparations
  • Methylphenidate
  • Atomoxetine Hydrochloride